Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
Introduction
Spleen tyrosine kinase (Syk) is an intracellular protein tyrosine kinase that serves as a key mediator of Fc receptor and B cell receptor signaling in inflammatory cells, including mast cells, macrophages, dendritic cells (DC), NK cells, and neutrophils. Through its interaction with the phosphorylated gamma chains of the heterodimeric Fcγ receptors, Syk is essential for the signal transduction initiated by activated receptors for immunoglobulin G. Aggregation of the Fc receptors, induced by antibody–antigen complexes, can induce many cellular functions including phagocytosis, degranulation, NK cell antibody-dependent cellular cytotoxicity, and cytokine secretion, depending on the cell type. The initiation of inflammatory and destructive responses by these effector cells is believed to be crucial for the development and pathogenesis of autoimmunity [1]. Immune complex (IC)-mediated acute inflammatory tissue injury has been implicated not only in rheumatoid arthritis (RA), but in a variety of human autoimmune diseases, including systemic lupus erythematosus and certain types of glomerulonephritis [2], [3].
Several recent studies in Fc receptor (FcR)-deficient mouse strains suggest that signaling through this receptor is the critical step in the progression of tissue destruction in murine models of inflammation [4], [5], [6], [7]. In KRN TCR transgenic mice, in which the arthritis is chronic and symmetric with pannus formation and destructive lesions of joints and bones, FcγRIII-deficient mice have markedly diminished paw swelling following treatment with K/BxN serum, and mast cell-deficient mice have markedly attenuated synovitis [5]. Ji et al. [8] confirmed that the arthritogenic immunoglobulins act through Fc receptors (FcγRIII and complement). Furthermore, in mice immunized with collagen, on an arthritis susceptible DBA background, mice lacking FcRγ chains were protected relative to wild-type controls, although both groups produced similar levels of anti-collagen antibody [6].
Despite extensive efforts, the etiology and pathogenesis of RA remain poorly understood, and numerous cell populations have been implicated including T cells, B cells, monocytes/macrophages, mast cells, dendritic cells and fibroblasts [9]. Chemokines, matrix metalloproteinases, adhesion molecules, angiogenic growth factors, and dysregulated intra-articular expression of proinflammatory cytokines (in particular IL-1β and TNFα) play key roles in the pathogenesis of RA [10]. It is known that complement is activated in RA synovial fluids, and complement components are even locally produced [11]. Moreover, immune complexes are deposited at the cartilage level [12]. Humoral mediators may play a role as well; rheumatoid factors, found in 90% of patients, are associated with a poor prognosis. Genetic linkage studies implicate FcR polymorphisms as a potentially important disease susceptibility factor. In humans, there are three classes of FcγR (I–III); the level of expression and localization of FcγR (activating and inhibitory) restricts specific biological properties to certain cell types. Functional polymorphic variants within FCRG2A or FCRG2B, or within FCGR3A or FCGR3B, may additionally contribute to disease susceptibility and pathogenesis [13], [14], [15], [16], [17]. FcγR polymorphisms appear to be important predisposing factors in systemic lupus erythematosus (SLE) and multiple sclerosis (MS) [15], [18]. In addition, IgG receptor polymorphisms are also reported to influence the efficacy of intravenous immunoglobulin therapy for patients with autoimmune diseases [19].
The effects of a novel small molecule, R406, have been examined in several cell systems, and its activity is consistent with Syk inhibition in isolated mast cells, macrophages, DC, and synoviocytes. R406 potently inhibits IgG and IgE-induced mast cell degranulation in cell-based assays with an EC50 of approximately 50 nM [20], [21]. Selectivity towards Syk inhibition was demonstrated in mast cells activated by FcεR1 cross-linking, in which R406 inhibited the phosphorylation of linker for activation of T cell (LAT) tyrosine Y191 (a Syk substrate) about 50-fold more potently than the phosphorylation of Syk itself, which is phosphorylated by Lyn kinase. Subsequent signaling events in that pathway, including JNK and ERK1/2, but not p38, were also inhibited [21]. IC stimulation of DC cytokine secretion is also inhibited by R406. R406 prevented cytokine release (IL-13) from DC isolated from the bone marrow of ovalbumin (OVA)-sensitized mice and cultured in the presence of R406 and OVA-IgG immune complexes [22]. Recent data implicate Syk signaling in TNFα-induced inflammatory cytokine and matrix metalloproteinase (MMP) production by fibroblast-like synoviocytes (FLS) isolated from joint tissues of RA patients [23], and treatment of cultured FLS with R406 markedly suppressed TNFα-induced IL-6 and MMP-3 production in RA FLS. Syk is an attractive target for immune and inflammatory diseases because inhibition of Syk can suppress numerous overlapping pathways simultaneously [1], [23], [24].
Given that Syk has a pivotal role in mediating FcR activation in hematopoietic cells, we investigated R406 and R788 (prodrug of R406) for their capacity to suppress the reverse passive Arthus (RPA) reaction and collagen-induced arthritis (CIA).
Section snippets
Animals
Female Sprague–Dawley rats (Hilltop Laboratories, Scottdale, PA), aged 8–10 weeks, were used in the Arthus studies. For CIA, female Lewis rats, aged 6–8 weeks, were purchased from Harlan Laboratories (Indianapolis, IN), and syngeneic LOUVAIN (LOU) rats were inbred at UCLA (Los Angeles, CA). In-life procedures were approved for each model by the respective Institutional Animal Care and Use Committee.
R788/R406
R406 was synthesized and was also prepared as a soluble prodrug (R788). R406 is soluble in a
R788/R406 inhibit the Arthus reaction
Since FcγR (I, III) expressed on synovial macrophages are critical in the onset of IC-mediated inflammation, R406 and R788 activity was assessed in the RPA reaction. IC formation produced a severe Arthus reaction beginning within minutes after antigen/antibody injection, which increased in severity for 4–8 h. Prophylactic treatment of rats with R406 or R788 administered 1 h prior to IC challenge resulted in a significant reduction (p < 0.05) in vascular leakage (Fig. 1), and the severity of local
Discussion
The results reported here demonstrate for the first time that inhibition of FcγR signaling via Syk can completely suppress joint inflammation and bone erosion in CIA. The pharmacological anti-inflammatory potential of R788, a prodrug of R406, to inhibit activating FcR signaling was initially demonstrated in a cutaneous reverse passive Arthus reaction, in which inhibition of FcR signal transduction reduces the IC-mediated inflammatory response [30], [31]. In the CIA model, treatment of arthritic
Acknowledgments
The authors gratefully acknowledge Abraham Silvers for the statistical evaluation of clinical arthritis, Muhammad Baluom for the pharmacokinetic analysis, and Anne Ponugoti for graphics assistance.
References (57)
- et al.
A dominant role for mast cell Fc receptors in the Arthus reaction
Immunity
(1996) - et al.
Arthritis critically dependent on innate immune system players
Immunity
(2002) - et al.
Fcγ receptors: old friends and new family members
Immunity
(2006) - et al.
IgG polymorphisms in human disease: implications for intravenous immunoglobulin therapy
J. Allergy Clin. Immunol.
(2003) - et al.
Organ-specific disease provoked by systemic autoimmunity
Cell
(1996) - et al.
Rhematoid Arthritis
Cell
(1996) - et al.
CTLA-4Ig: bridging the basic immunology with clinical application
Immunity
(2006) - et al.
Targeting Syk as a treatment for allergic and autoimmune disorders
Expert Opin. Investig. Drugs
(2004) Roles of Fc receptors in autoimmunity
Nat. Rev., Immunol.
(2002)- et al.
IgG Fc receptors
Annu. Rev. Immunol.
(2001)
Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis
J. Immunol.
The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis
J. Immunol.
Induction and suppression of collagen-induced arthritis is dependent on distinct Fcgamma receptors
J. Exp. Med.
Therapeutic strategies for rheumatoid arthritis
Nat. Rev.
Common mechanisms in immune-mediated inflammatory diseases
J. Rheumatol.
Local production of complement proteins in rheumatoid arthritis synovium
Arthritis Rheum.
Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage
Arthritis Rheum.
A novel polymorphism of Fcgamma RIIIa (CD16) alters receptor function and predisposes to autoimmune disease
J. Clin. Invest.
Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans
J. Clin. Invest.
A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling
Arthritis Rheum.
Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B
Arthritis Res. Ther.
Immunoglobulin G Fc-receptor (FcγR)IIA and IIIB polymorphisms related to disability in MS
Neurology
R406, an orally bioavailable spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
J. Pharmacol. Exp. Ther.
Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness
Am. J. Respir. Crit. Care Med.
Syk activation in dendritic cells is essential to the development of airway hyperresponsiveness and inflammation
Am. J. Respir. Cell Mol. Biol.
The novel Syk inhibitor R406 blocks JNK-mediated gene expression in synoviocytes
J. Pharmacol. Exp. Ther.
TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kB activation, and apoptosis
J. Immunol.
Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel anti-inflammatory agent with a combined mechanism of action
J. Rheumatol.
Cited by (189)
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
2023, Bioorganic and Medicinal ChemistryLow-molecular-weight fucoidan ameliorates calcium-deficient-diet–induced bone loss and osteoarthritis via CaSR level regulation
2023, Journal of Functional FoodsA bioinformatics system for exploring potential targets and therapies in rheumatoid arthritis
2023, Healthcare Analytics